Ticagrelor [ticagrelor]
topical
76
- Terms
-
(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-difluorofenyl)cyklopropyl]amino]-5-propylsulfanyltriazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyklopentan-1,2-diol
Brilique
Ticagrelor Mylan
tikagrelor
-
3-(7-((2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-(1-3)-triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
AZD 6140
AZD-6140
AZD6140
Brilinta
Brilique
Persistent link
https://www.medvik.cz/link/D000077486
Definition
An adenosine triphosphate analogue and reversible P2Y12 PURINORECEPTOR antagonist that inhibits ADP-mediated PLATELET AGGREGATION. It is used for the prevention of THROMBOEMBOLISM by patients with ACUTE CORONARY SYNDROME or a history of MYOCARDIAL INFARCTION.
- DUI
- D000077486 MeSH Browser
- CUI
- M0513890
- CAS
- 1,2-cyclopentanediol, 3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-1,2,3-triazolo(4,5-d)pyrimidin-3-yl)-5-(2-hydroxyethoxy)-, (1S,2S,3R,5S)-
- History note
- 2019 (2005)
- Public note
- 2019; TICAGRELOR was indexed under ADENOSINE/analogs&derivatives 2005-2018
Allowable subheadings
- AD
- administration & dosage 22
- AE
- adverse effects 17
- AG
- agonists
- AN
- analysis
- AI
- antagonists & inhibitors
- BL
- blood
- CF
- cerebrospinal fluid
- CS
- chemical synthesis
- CH
- chemistry 1
- CL
- classification
- EC
- economics 1
- HI
- history
- IM
- immunology
- IP
- isolation & purification
- ME
- metabolism
- PK
- pharmacokinetics 2
- PD
- pharmacology 14
- PO
- poisoning
- RE
- radiation effects
- ST
- standards
- SD
- supply & distribution
- TU
- therapeutic use 34
- TO
- toxicity
- UR
- urine
...
Occurrences in Medvik records
D
Chemicals and Drugs
D03.633.100.759.590.138.630
Phenylisopropyladenosine
D13.570.583.138.630
Phenylisopropyladenosine
D13.570.800.096.630
Phenylisopropyladenosine